Natera announced the publication of a prospective clinical trial on its Prospera platform in the journal Transplantation Direct. The study, conducted by Ohio State University Wexner Medical Center, enrolled 78 lung‑transplant recipients and followed them for 12 months.
The trial found that Prospera‑guided monitoring reduced the average number of transbronchial biopsies from 4.2 per patient to 2.8, a 33% decrease, while maintaining a 95% sensitivity for detecting acute rejection. The study also reported that the proportion of patients with missed rejection events was less than 1%, comparable to standard care.
The findings underscore the potential of donor‑derived cell‑free DNA to replace or supplement invasive biopsies, a key pain point for transplant centers. By lowering biopsy frequency, Prospera could reduce procedural complications, lower costs, and improve patient quality of life.
For Natera, the study strengthens the clinical evidence base for its organ‑health segment, which the company has identified as a high‑growth area. The company’s broader strategy is to expand Prospera’s use beyond lung transplantation to kidney, heart, and liver transplants, leveraging the same cfDNA technology.
The publication arrives amid strong financial performance, with Q4 2024 revenue up 53% to $476.1 million and gross margin at 62.9%. Management has expressed confidence that the clinical validation will accelerate adoption and drive future revenue growth in the organ‑health market.
The study’s impact factor of 2.1 for Transplantation Direct and the involvement of a leading transplant research center add credibility to the results, positioning Natera as a leader in non‑invasive transplant monitoring.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.